Sep 2 |
Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025?
|
Aug 15 |
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
|
Aug 12 |
Savara GAAP EPS of -$0.12 misses by $0.01
|
Aug 12 |
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
|
Jul 5 |
Savara Inc.'s (NASDAQ:SVRA) high institutional ownership speaks for itself as stock continues to impress, up 14% over last week
|
Jun 30 |
Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?
|
Jun 28 |
Savara prices ~$100M stock offering
|
Jun 28 |
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
|
Jun 26 |
Savara: Today's Data 'Win' Rouses Market All Too Briefly
|
Jun 26 |
Savara surges after late-stage trial win for lead asset against rare lung disease
|